LU92397I2 - Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable - Google Patents

Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable

Info

Publication number
LU92397I2
LU92397I2 LU92397C LU92397C LU92397I2 LU 92397 I2 LU92397 I2 LU 92397I2 LU 92397 C LU92397 C LU 92397C LU 92397 C LU92397 C LU 92397C LU 92397 I2 LU92397 I2 LU 92397I2
Authority
LU
Luxembourg
Prior art keywords
vortioxetine
pharmaceutically acceptable
acid addition
addition salt
acceptable acid
Prior art date
Application number
LU92397C
Other languages
English (en)
French (fr)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92397(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of LU92397I2 publication Critical patent/LU92397I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
LU92397C 2001-10-04 2014-03-12 Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable LU92397I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200101466 2001-10-04

Publications (1)

Publication Number Publication Date
LU92397I2 true LU92397I2 (fr) 2014-05-12

Family

ID=8160750

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92397C LU92397I2 (fr) 2001-10-04 2014-03-12 Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable

Country Status (38)

Country Link
US (10) US7144884B2 (en, 2012)
EP (2) EP1436271B3 (en, 2012)
JP (3) JP3896116B2 (en, 2012)
KR (3) KR100842702B1 (en, 2012)
CN (1) CN1319958C (en, 2012)
AR (2) AR036659A1 (en, 2012)
AT (2) ATE441631T1 (en, 2012)
AU (2) AU2002333220C1 (en, 2012)
BE (1) BE2014C036I2 (en, 2012)
BR (3) BRPI0212733B8 (en, 2012)
CA (1) CA2462110C (en, 2012)
CO (1) CO5580746A2 (en, 2012)
CY (3) CY1107924T1 (en, 2012)
DE (2) DE60233608D1 (en, 2012)
DK (2) DK1749818T3 (en, 2012)
EA (2) EA007537B3 (en, 2012)
EG (1) EG25095A (en, 2012)
ES (2) ES2328725T3 (en, 2012)
FR (1) FR14C0033I2 (en, 2012)
HR (1) HRP20040220A2 (en, 2012)
HU (3) HU228956B1 (en, 2012)
IL (1) IL160655A0 (en, 2012)
IS (2) IS2578B (en, 2012)
LT (1) LTC1436271I2 (en, 2012)
LU (1) LU92397I2 (en, 2012)
ME (1) ME00039B (en, 2012)
MX (1) MXPA04002959A (en, 2012)
MY (1) MY140950A (en, 2012)
NL (1) NL300652I1 (en, 2012)
NO (3) NO326443B1 (en, 2012)
NZ (1) NZ531556A (en, 2012)
PL (2) PL210551B1 (en, 2012)
PT (2) PT1749818E (en, 2012)
RS (2) RS52865B (en, 2012)
SI (1) SI1436271T1 (en, 2012)
UA (2) UA81749C2 (en, 2012)
WO (1) WO2003029232A1 (en, 2012)
ZA (1) ZA200401583B (en, 2012)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
MXPA05009592A (es) * 2003-04-04 2005-10-18 Lundbeck & Co As H Derivados de 4-(2-fenilsulfanil-fenil)-piperidina como inhibidores de recaptacion de serotonina.
BRPI0408647A (pt) * 2003-04-04 2006-03-07 Lundbeck & Co As H composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
EP1635828B1 (en) * 2003-04-04 2008-04-23 H. Lundbeck A/S 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
KR20050119682A (ko) * 2003-04-04 2005-12-21 하. 룬트벡 아크티에 셀스카브 세로토닌 재흡수 억제제로서 4-(2-페닐옥시페닐)-피페리딘또는 -1,2,3,6-테트라히드로피리딘 유도체
WO2005061455A1 (en) 2003-12-23 2005-07-07 H. Lundbeck A/S 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
AR052308A1 (es) 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
US7923444B2 (en) 2005-02-10 2011-04-12 Neurosearch A/S Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
AR054393A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
KR101445514B1 (ko) * 2006-06-16 2014-09-29 하. 룬트벡 아크티에 셀스카브 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
WO2007144006A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
RS51687B (en) * 2006-06-16 2011-10-31 H. Lundbeck A/S. CRYSTAL FORMS 4- [2-4- (4-METHYLPHENYLSULPHANYL) PHENYL] PIPERIDINE WITH COMBINED INHIBITION OF SEROTONIN AND NOREPINEPHRINE REASPORPTION FOR TREATMENT OF NEUROPATIC PAIN
UA95801C2 (ru) * 2006-06-16 2011-09-12 Х. Луннбек А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)-фенил]пиперидина с комбинированным ингибированием обратного захвата серотонина и норэпинефрина для лечения невропатической боли
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
JP5764327B2 (ja) * 2007-06-15 2015-08-19 ハー・ルンドベック・アクチエゼルスカベット 過敏性腸症候群（ｉｂｓ）を処置するための４−［２−（４−メチルフェニルスルファニル）フェニル］ピペリジン
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
WO2009081259A1 (en) * 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
UA98698C2 (en) * 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
EP2358674B1 (en) 2008-11-14 2013-01-02 Theravance, Inc. Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
RS53539B1 (en) 2009-04-24 2015-02-27 H. Lundbeck A/S LIQUID FORMULATIONS OF SALES 1- [2- (2,4-DIMETHYLPHENYLSULPHANYL) PHENYL] PIPERAZINE
NZ598083A (en) * 2009-08-24 2013-08-30 Lundbeck & Co As H New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
CA2779108C (en) * 2009-10-30 2018-01-02 Janssen Pharmaceutica Nv 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators
WO2011085291A1 (en) 2010-01-11 2011-07-14 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
US8530663B2 (en) * 2010-03-22 2013-09-10 Theravance, Inc. 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
KR20130060220A (ko) 2010-04-30 2013-06-07 다케다 야쿠힌 고교 가부시키가이샤 장용성 정제
MY162392A (en) * 2010-04-30 2017-06-15 Takeda Pharmaceuticals Co Enteric tablet
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
ES2601213T3 (es) 2011-06-20 2017-02-14 H. Lundbeck A/S 1-piperazino-3-fenil-indanos deuterados para el tratamiento de la esquizofrenia
RU2622082C2 (ru) 2011-11-14 2017-06-09 Нестек С.А. Анализы и способы выбора режима лечения пациента с депрессией
RU2608307C2 (ru) * 2012-01-03 2017-01-17 Х.Лундбек А/С Способ получения 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
CN104797566B (zh) 2012-09-19 2017-07-07 桑多斯股份公司 沃替西汀氢溴酸盐的新结晶形式
MY171802A (en) 2012-12-13 2019-10-30 H Lundbeck As Compositions comprising vortioxetine and donepezil
LT2958903T (lt) * 2013-02-22 2017-08-25 H. Lundbeck A/S Vortioksetino gamybos būdas
US9493409B2 (en) 2013-04-04 2016-11-15 Lek Pharmaceuticals D.D. Process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine
CN104109135B (zh) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
IN2013MU03121A (en, 2012) 2013-09-30 2015-07-17 Cadila Healthcare Ltd
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
EP3082815B1 (en) 2013-12-20 2018-10-03 H. Lundbeck A/S Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
EP2894154A1 (en) * 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
CN106103418A (zh) 2014-01-31 2016-11-09 埃吉斯药物私人有限公司 沃替西汀盐的制备方法
EP2930171A1 (en) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104059030B (zh) 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) * 2014-07-03 2017-03-10 Ifp Energies Now Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs) 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
ES2634496T3 (es) 2014-11-21 2017-09-28 Dipharma Francis S.R.L. Proceso para la preparación de un antidepresivo y los intermedios del mismo
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
EP3262031A1 (en) 2015-02-25 2018-01-03 Lupin Limited Process for the preparation of vortioxetine
WO2016151328A1 (en) 2015-03-26 2016-09-29 Cipla Limited Method for making serotonin reuptake inhibitors
CN104829557B (zh) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
MX386470B (es) 2015-07-17 2025-03-18 Pasteur Institut Agente estimulador del receptor 5-hidroxi triptamina 1b para usarse como un promotor de la autorrenovación y/o diferenciación de células satélite.
EP3337789A1 (en) * 2015-08-19 2018-06-27 Amneal Pharmaceuticals Company GmbH Process for preparation of vortioxetine hydrobromide
WO2017063771A1 (en) * 2015-10-14 2017-04-20 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
US11013830B2 (en) 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
RU2018144248A (ru) * 2016-07-01 2020-08-03 Х. Лундбекк А/С Схемы дозирования вортиоксетина для быстрого появления антидепрессивного эффекта
EP3484462B1 (en) 2016-07-15 2022-12-14 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair
KR20190032418A (ko) * 2016-07-22 2019-03-27 지앙수 인화뤄캉 파마슈티컬 리서치 앤드 디벨롭먼트 컴퍼니 리미티드 보티옥세틴 유사체와 용도 및 이의 제조
US20190224192A1 (en) 2016-08-29 2019-07-25 Cipla Limited Stable Pharmaceutical Composition of Vortioxetine Hydrobromide
CN106349132B (zh) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409728B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
WO2018150344A1 (en) 2017-02-17 2018-08-23 Unichem Laboratories Ltd Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
EP3585388A4 (en) 2017-02-23 2020-08-12 Unichem Laboratories Ltd IMPROVED PROCESS FOR PREPARATION AND PURIFICATION OF VORTIOXETINE BROMHYDRATE
MA49056A (fr) * 2017-04-25 2020-03-04 H Lundbeck As Procédé de fabrication de la forme alpha de vortioxétine hbr
EP3412661A1 (en) 2017-06-08 2018-12-12 Enantia, S.L. Cocrystals of vortioxetine hydrobromide and resorcinol
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN107915685A (zh) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
WO2019242889A1 (en) 2018-06-20 2019-12-26 Vio Ag Pharmaceuticals S.A. A one-pot organo-pseudocatalytic c-h activation approach for the preparation of vortioxetine and vortioxetine intermediate
CN108863986B (zh) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 二氟甲基取代的苯基哌嗪衍生物及其用途
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
AU2021246973A1 (en) 2020-04-03 2022-11-03 H. Lundbeck A/S 1-(2-(2,4-dimethylphenylsulfanyl)-phenyl)piperazine for prevention or treatment of emotional blunting
US12281088B2 (en) 2020-09-10 2025-04-22 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Process for the synthesis of vortioxetine
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine
WO2025132869A1 (en) 2023-12-21 2025-06-26 H. Lundbeck A/S Method for the preparation of vortioxetine pharmaceutical compositions with low amounts of nitrosamine impurities

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151751B1 (en, 2012) 1971-04-13 1973-11-19
CS151752B1 (en, 2012) 1971-04-13 1973-11-19
CS151753B1 (en, 2012) 1971-04-13 1973-11-19
CS151755B1 (en, 2012) 1971-04-13 1973-11-19
YU163075A (en) 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198419A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
ES2004809A6 (es) 1987-07-29 1989-02-01 Ferrer Int Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
WO1996022977A1 (fr) 1995-01-23 1996-08-01 Suntory Limited Ameliorant ou remede contre des symptomes provoques par des maladies ischemiques et composes utiles a cet effet
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ES2230209T3 (es) * 1997-10-31 2005-05-01 Daiichi Suntory Pharma Co., Ltd. Procedimiento para preparar n-((4-fenil)metilfenil)piperazinas.
AU774054B2 (en) 1999-04-02 2004-06-17 Icos Corporation Inhibitors of LFA-1 binding to ICAMs and uses thereof
WO2001010842A2 (en) 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
CA2384599A1 (en) * 1999-09-14 2001-03-22 Pharmacopeia, Inc. Article comprising a multi-channel dispensing head
ATE261959T1 (de) * 1999-12-30 2004-04-15 Lundbeck & Co As H Substituierte phenyl-piperazin-derivate, deren herstellung und verwendung
EP1246819A1 (en) * 1999-12-30 2002-10-09 H. Lundbeck A/S A method for the preparation of substituted benzene derivatives
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (de) 2000-07-11 2002-05-16 Wolfgang Papenbrock Verfahren zur Vorschau von Internetseiten
EP1370558B1 (en) 2001-01-23 2005-08-24 Eli Lilly And Company Piperazine- and piperidine-derivatives as melanocortin receptor agonists
EP1363890A4 (en) 2001-02-07 2009-06-10 Ore Pharmaceuticals Inc MELANOCORTIN-4-RECEPTOR BINDING COMPOUNDS AND METHOD FOR THEIR APPLICATION
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
EP1458689B1 (en) * 2001-12-20 2007-04-11 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
MXPA05009592A (es) * 2003-04-04 2005-10-18 Lundbeck & Co As H Derivados de 4-(2-fenilsulfanil-fenil)-piperidina como inhibidores de recaptacion de serotonina.
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
KR101445514B1 (ko) * 2006-06-16 2014-09-29 하. 룬트벡 아크티에 셀스카브 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진

Also Published As

Publication number Publication date
IS2732B (is) 2011-04-15
KR20060118020A (ko) 2006-11-17
CY1110064T1 (el) 2015-01-14
ES2298425T3 (es) 2008-05-16
ES2298425T7 (es) 2022-06-27
BR122012009534C8 (pt) 2021-05-25
DE60225162T3 (de) 2022-08-11
EA007537B1 (ru) 2006-10-27
US7683053B2 (en) 2010-03-23
PT1749818E (pt) 2009-10-06
NO326443B1 (no) 2008-12-08
KR20040047886A (ko) 2004-06-05
US7144884B2 (en) 2006-12-05
ME00039B (me) 2010-06-10
IS8806A (is) 2009-03-10
EA011096B1 (ru) 2008-12-30
ATE386730T1 (de) 2008-03-15
US20120302553A1 (en) 2012-11-29
EP1749818B1 (en) 2009-09-02
JP3955614B2 (ja) 2007-08-08
NO332355B1 (no) 2012-09-03
EA200601269A1 (ru) 2007-02-27
SI1436271T1 (sl) 2008-06-30
US8110567B2 (en) 2012-02-07
US20050014740A1 (en) 2005-01-20
DK1436271T6 (da) 2022-06-27
KR100842702B1 (ko) 2008-07-01
EP1436271A1 (en) 2004-07-14
AU2006215994A1 (en) 2006-10-05
EA007537B3 (ru) 2015-02-27
PL368442A1 (pl) 2005-03-21
EP1436271B3 (en) 2022-04-20
US7138407B2 (en) 2006-11-21
DE60225162T2 (de) 2009-02-12
UA81749C2 (uk) 2008-02-11
NZ531556A (en) 2005-12-23
RS52326B (en) 2012-12-31
KR100770194B1 (ko) 2007-10-25
US20140163043A1 (en) 2014-06-12
IS2578B (is) 2010-02-15
BR122012023120B8 (pt) 2022-01-18
KR20070103515A (ko) 2007-10-23
US20160137620A1 (en) 2016-05-19
KR100783346B1 (ko) 2007-12-07
NO2014011I2 (no) 2015-08-31
HUP0402313A2 (hu) 2005-02-28
CO5580746A2 (es) 2005-11-30
PL209253B1 (pl) 2011-08-31
BR122012009534B8 (pt) 2019-01-29
AU2006215994A2 (en) 2006-10-05
NO20041628L (no) 2004-04-21
CY1107924T1 (el) 2013-09-04
CN1319958C (zh) 2007-06-06
IL160655A0 (en) 2004-07-25
US20070060574A1 (en) 2007-03-15
JP2005505585A (ja) 2005-02-24
ATE441631T1 (de) 2009-09-15
AU2002333220C1 (en) 2023-10-05
CA2462110E (en) 2003-04-10
US7148238B2 (en) 2006-12-12
EG25095A (en) 2011-08-17
RS20120158A2 (en) 2012-10-31
EP1749818A3 (en) 2008-04-02
US20060084662A1 (en) 2006-04-20
EA200400498A1 (ru) 2004-08-26
NO20083446L (no) 2004-04-21
UA93857C2 (uk) 2011-03-25
CA2462110A1 (en) 2003-04-10
AU2002333220B2 (en) 2008-02-07
US20060089368A1 (en) 2006-04-27
CN1561336A (zh) 2005-01-05
RS52865B (en) 2013-12-31
CA2462110C (en) 2010-05-11
BR122012023120B1 (pt) 2017-03-21
HK1072600A1 (en) 2005-09-02
US9708280B2 (en) 2017-07-18
FR14C0033I1 (en, 2012) 2014-06-13
NL300652I2 (en, 2012) 2016-01-18
WO2003029232A1 (en) 2003-04-10
DE60225162D1 (de) 2008-04-03
HRP20040220A2 (en) 2005-02-28
US10844029B2 (en) 2020-11-24
JP3955613B2 (ja) 2007-08-08
JP3896116B2 (ja) 2007-03-22
AU2006215994A9 (en) 2006-10-05
NO2014011I1 (no) 2014-05-13
DK1749818T3 (da) 2009-10-12
RS27704A (en) 2006-10-27
NL300652I1 (en, 2012) 2016-01-18
BR122012009534B1 (pt) 2018-02-27
US8476279B2 (en) 2013-07-02
ZA200401583B (en) 2005-05-25
MY140950A (en) 2010-02-12
JP2007051149A (ja) 2007-03-01
AR036659A1 (es) 2004-09-22
US20110009423A1 (en) 2011-01-13
BRPI0212733B8 (pt) 2021-05-25
RS20120158A3 (en) 2013-10-31
AR066460A2 (es) 2009-08-19
JP2007031447A (ja) 2007-02-08
AU2002333220A2 (en) 2003-04-14
MEP6508A (xx) 2010-02-10
EP1749818A2 (en) 2007-02-07
ES2328725T3 (es) 2009-11-17
LTC1436271I2 (lt) 2016-09-12
US20180127389A1 (en) 2018-05-10
US20210276966A1 (en) 2021-09-09
DE60233608D1 (de) 2009-10-15
BE2014C036I2 (en, 2012) 2021-11-22
CY2014022I1 (el) 2015-12-09
HU228956B1 (en) 2013-07-29
BR0212733B1 (pt) 2014-05-13
MXPA04002959A (es) 2004-07-05
PT1436271E (pt) 2008-04-10
AU2006215994B2 (en) 2008-11-13
PL210551B1 (pl) 2012-02-29
EP1436271B1 (en) 2008-02-20
CY2014022I2 (el) 2015-12-09
BR0212733A (pt) 2004-11-16
FR14C0033I2 (fr) 2014-11-14
HUP0402313A3 (en) 2010-03-29
DK1436271T3 (da) 2008-06-09
HU230189B1 (hu) 2015-09-28
IS7164A (is) 2004-02-26
US9090575B2 (en) 2015-07-28
HUS1400012I1 (hu) 2020-12-28

Similar Documents

Publication Publication Date Title
LU92397I2 (fr) Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable
LU93320I2 (fr) Everolimus ou un sel pharmaceutiquement acceptable de celui-ci
LU92520I2 (fr) Bédaquiline, ou son sel d'addition d'acide ou de base pharmaceutiquement acceptable, y compris le fumarate de bédaquiline
LU92943I2 (fr) Ceftolozane ou un sel pharmaceutiquement acceptable, en particulier un sel d'acide sulfurique (zerbaxa)
FR2817306B1 (fr) Systeme d'entrainement
EE200200716A (et) Ühendid Alzheimeri tõve käitluseks
LU92826I2 (fr) Lubiprostone, incluant les sels pharmaceutiquementacceptables, les esters ou les amides de la lubip rostone
FR2812203B1 (fr) Appareil d'aide a la ventilation d'un patient
MA27126A1 (fr) 3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
EP1286136A4 (en) INERTIA CONVERTER
ZA200403373B (en) Novel benzophenone derivatives or salts thereof
MA25984A1 (fr) Procede pour preparation de maleate d'amlodipine.
EP1293131A4 (en) MEANS FOR CLEANING TREATMENT
ECSP045162A (es) "composiciones farmaceuticas a base de derivados de azetidina"
FR2818979B1 (fr) Procede de preparation d'imidaclopride
EE200200554A (et) Galantamiini või selle farmatseutiliselt sobiva soola kasutamine
ITMI20012197A0 (it) Sistema di ausilio all'arbitraggio di un incontro di calcio
GB0012123D0 (en) Alzheimer's disease assay
AU2002364885A1 (en) Alzheimer's disease model
FR2819984B1 (fr) Dispositif pour la preparation de racines d'endives destinees a la production de chicons
PL368419A1 (en) Novel $g(a)-oxygenated or $g(a)-thiolated carboxylic acid phenethylamide derivatives
MA25828A1 (fr) Procede de preparation d'oligomeres de galactomannanes
ITMI20000810A0 (it) Procedimento per la preparazione di 5'-acetilstavudina
FR2829806B3 (fr) Ensemble d'helice perfectionne
ES1044904Y (es) "badajo"